About this trial
Objectives: To evaluate the effectiveness of toothpaste tablets when compared to conventional dentifrices in removing plaque.
Methods: 50 participants are randomized into two groups: Denttabs toothpaste tablets (T) and Colgate's Cavity Protection toothpaste (P). Both groups utilize their assigned dentifrice for 6 weeks. A pre and post-assessment measures the Gingival Index (GI) and Plaque Index (PI) and Decayed, Missing and Filled Teeth (DMFT). A questionnaire on the use of the product is distributed at the end of the study.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Subjects are 18 years or older;
Subjects who will comply with study protocol;
Subjects who can read and understand the consent form;
Subjects available during the study period;
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Toothpaste Tablet
DrugDenttabs toothpaste tablets
Conventional Toothpaste
DrugColgate Cavity Protection toothpaste
Treatment groups
Trial outcomes
Primary outcomes
Plaque Index Score at Baseline
The quantity of plaque build-up is measured visually using the Quigley-Hein Plaque Index. The Plaque index can range from 0 to 5, with higher numbers indicating more plaque build-up.
Gingival Index Score at Baseline
The severity of gingival inflammation is measured visually using the Loe-Silness Gingival Index. Gingival index can range from 0 to 3, with higher numbers indicating more gingival inflammation.
Secondary outcomes
DMFT Score at Baseline
Caries experiences is measured visually using the DMFT index. DMFT score can range from 0 to 28, with higher numbers indicating higher caries experiences.
Subject Perception of Product Use
The perception on the product usage is measured using a survey containing questions on feel, texture, flavor, ease of use, eco-friendliness, cost and overall satisfaction. Response is on a 4 point Likert scale ranging from strongly agree (1) to strongly disagree (4).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: